Cargando…

Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial

OBJECTIVE: The study assessed the efficacy, safety, pharmacokinetic (PK), and immunogenicity profiles of denosumab-biosimilar and denosumab-reference in postmenopausal osteoporotic women from India. MATERIALS AND METHODS: In this randomized, assessor-blind, active-control, multicenter trial, 114 pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Inderjeet, Jose, Vinu, Patel, Ronak, Arora, Sumit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216120/ https://www.ncbi.nlm.nih.gov/pubmed/33975993 http://dx.doi.org/10.4103/ijp.IJP_346_19

Ejemplares similares

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
por: Gu, Jiemei, et al.
Publicado: (2022)

Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar(®) in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
por: TABATABAEI-MALAZY, Ozra, et al.
Publicado: (2018)

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension
por: Koh, Jung-Min, et al.
Publicado: (2016)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
por: Pitale, Shailesh, et al.
Publicado: (2015)

Effect of folic acid on bone metabolism: a randomized double blind clinical trial in postmenopausal osteoporotic women
por: Salari, Pooneh, et al.
Publicado: (2014)

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
por: Karnon, Jonathan, et al.
Publicado: (2016)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women
por: Passeri, Elena, et al.
Publicado: (2015)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
por: Jamshidi, Ahmadreza, et al.
Publicado: (2022)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
por: Liu, Ting-Chun, et al.
Publicado: (2023)

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women
por: Fenwick, Steven, et al.
Publicado: (2022)

Audiovestibular Symptoms in Osteoporotic Postmenopausal Dominican Women
por: Acra-Tolari, Ricardo, et al.
Publicado: (2022)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
por: Ding, Yanhua, et al.
Publicado: (2023)

Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial
por: Prasad, Trupti Nagendra, et al.
Publicado: (2023)

Vitamin D inadequacy in Belgian postmenopausal osteoporotic women
por: Neuprez, Audrey, et al.
Publicado: (2007)

Clinical manifestations of osteoarthritis in osteoporotic and osteopenic postmenopausal women
por: Rizou, Stavroula, et al.
Publicado: (2018)

Efficacy and Safety of Electroacupuncture for Insomnia Disorder: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
por: Lee, Boram, et al.
Publicado: (2020)

Blinding of outcome assessors and its association with outcome in a randomized open-label stroke trial
por: van der Ende, Nadinda AM, et al.
Publicado: (2022)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

The effect of consumption of garlic tablet on proteins oxidation biomarkers in postmenopausal osteoporotic women: A randomized clinical trial
por: Ahmadian, Fereshte, et al.
Publicado: (2017)

Effect of aerobic exercise training on asthma control in postmenopausal women (the ATOM-study): protocol for an outcome assessor, randomised controlled trial
por: Hansen, Erik Sören Halvard, et al.
Publicado: (2021)

Infant skin-cleansing product versus water: A pilot randomized, assessor-blinded controlled trial
por: Lavender, Tina, et al.
Publicado: (2011)

Electro-acupuncture for central obesity: randomized, patient-assessor blinded, sham-controlled clinical trial protocol
por: Zhong, Linda L. D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_knce8rjggfek6n3auujt9l9k6p